Stock Price
25.08
Daily Change
0.43 1.74%
Monthly
-12.43%
Yearly
-38.38%
Q3 Forecast
24.54



Peers Price Chg Day Year Date
Terumo 2,262.50 16.50 0.73% -10.24% Sep/14
Abbott 101.95 -1.41 -1.36% -23.76% Sep/11
AngioDynamics 15.27 0.03 0.20% 43.38% Sep/11
Accuray 0.25 0.01 2.88% -84.08% Sep/11
AtriCure 54.54 1.58 2.98% 55.52% Sep/11
Baxter International 23.80 -0.38 -1.57% -0.79% Sep/11
Becton, Dickinson and Co. 177.85 1.43 0.81% -4.81% Sep/11
Boston Scientific 42.98 -0.12 -0.28% -58.15% Sep/11
Artivion 25.08 0.43 1.74% -38.38% Sep/11
Edwards Lifesciences 84.37 -2.40 -2.77% 8.77% Sep/11

Indexes Price Day Year Date
US2000 2904 12.99 0.45% 21.15% Sep/11

Artivion Inc traded at $25.08 this Friday September 11th, increasing $0.43 or 1.74 percent since the previous trading session. Looking back, over the last four weeks, Artivion gained 12.43 percent. Over the last 12 months, its price fell by 38.38 percent. Looking ahead, we forecast Artivion Inc to be priced at 24.54 by the end of this quarter and at 23.00 in one year, according to Trading Economics global macro models projections and analysts expectations.

CryoLife, Inc. (CryoLife), is a medical device company. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.